×
About 1,230 results

ALLMedicine™ Anaplastic Thyroid Cancer Center

Research & Reviews  393 results

ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyro...
https://doi.org/10.1007/s12020-022-03124-6
Endocrine Huang SS, Tsai CH et. al.

Jun 28th, 2022 - ATP-citrate lyase (ACLY) is a critical enzyme at the intersection of glucose and lipid metabolism. ACLY is often upregulated or activated in cancer cells to accelerate lipid synthesis and promote tumor progression. In this study, we aimed to explo...

"RB-reactivator screening" as a novel cell-based assay for discoveries of molecular tar...
https://doi.org/10.1016/j.pharmthera.2022.108234
Pharmacology & Therapeutics; Sakai T

Jun 23rd, 2022 - The retinoblastoma gene (RB) was discovered as the first tumor-suppressor gene. It was subsequently shown to be inactivated in most malignant tumors, particularly at the protein level. Therefore, many activated oncogenes as well as inactivated tum...

Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism.
https://doi.org/10.1097/XCS.0000000000000226
Journal of the American College of Surgeons; Zhao B, Aggarwal A et. al.

Jun 16th, 2022 - Anaplastic thyroid cancer (ATC) is an aggressive malignancy without effective treatments. ATC cells demonstrate upregulated glycolysis (Warburg effect), generating lactate that is subsequently exported by monocarboxylate transporter 4 (MCT4). This...

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
https://clinicaltrials.gov/ct2/show/NCT02034110

Jun 10th, 2022 - This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in combination with oral Trametinib in subjects with rare cancers including anaplastic thyroid cancer, biliary tract cancer, gastrointestinal stromal tumor, non-...

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT03122496

Jun 8th, 2022 - The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.

see more →

Guidelines  2 results

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349723
Thyroid : Official Journal of the American Thyroid Associ... Bible KC, Kebebew E et. al.

Mar 18th, 2021 - Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific ad...

Anaplastic Thyroid Carcinoma, Version 2.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  43 results

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
https://clinicaltrials.gov/ct2/show/NCT02034110

Jun 10th, 2022 - This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in combination with oral Trametinib in subjects with rare cancers including anaplastic thyroid cancer, biliary tract cancer, gastrointestinal stromal tumor, non-...

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT03122496

Jun 8th, 2022 - The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients
https://clinicaltrials.gov/ct2/show/NCT03733990

May 25th, 2022 - This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No s...

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT03975231

May 23rd, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability (maximum tolerated dose [MTD]) of concurrent intensity modulated radiation therapy (IMRT) and BRAF-MEK inhibitors dabrafenib and trametinib in patients with BRAF-mutated anaplastic thyro...

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
https://clinicaltrials.gov/ct2/show/NCT02034981

May 19th, 2022 - Twenty cohorts are identified, a cohort being defined as [one pathology, one target alteration] such as [gastric cancer with MET amplification (6%)]. One cohort will be dedicated to miscellaneous, very rare pediatric diseases identified through IN...

see more →

News  53 results

Targeted Treatment Boom Reshapes Differentiated Thyroid Cancer Landscape
https://www.onclive.com/view/targeted-treatment-boom-reshapes-differentiated-thyroid-cancer-landscape

Apr 18th, 2022 - Differentiated thyroid cancer (DTC) makes up approximately 95% of all thyroid cancers and is becoming more prevalent worldwide.1 A decade ago, treatment options for DTC were limited but today a plethora of targeted treatments are available. There ...

Mutation testing recommended for advanced and refractory thyroid cancer
https://www.mdedge.com/hematology-oncology/article/253582/head-neck/thyroid-cancers/mutation-testing-recommended-advanced
Jim Kling

Apr 8th, 2022 - A new consensus statement from the American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group focuses on a definition of advanced thyroid cancer and outlines strategies for mutation testing and targeted treat.

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Novel Treatment Advances in Differentiated Thyroid Cancer
https://www.onclive.com/view/novel-treatment-advances-in-differentiated-thyroid-cancer

Feb 3rd, 2022 - Lori Wirth, MD: So, listen, maybe Marcia, you can help us wrap up by helping us think about future directions in advance DTC [differentiated thyroid cancer]. Marcia Brose, MD, PhD, FASCO: I think that there’s a lot of future directions and I th...

Targeted Treatments for Differentiated Thyroid Cancer
https://www.onclive.com/view/targeted-treatments-for-differentiated-thyroid-cancer

Jan 6th, 2022 - Lori Wirth, MD: Maria, thank you for that. Let’s have you continue in terms of the general landscape of drugs that we have available for iodine-refractory advanced DTC [differentiated thyroid cancer]. Then Marcia, you could talk a little bit about...

see more →